NEW YORK (GenomeWeb) – Leidos and partner PositiveID have been awarded a contract from the US Defense Threat Reduction Agency (DTRA) to develop detection technologies for potential weapons of mass destruction.

Leidos is one of seven contractors eligible to compete for task orders under the DTRA contract, PositiveID said today. The multiple-award indefinite delivery/indefinite quantity contract has a five-year base period of performance, and if all options are exercised, it is valued at $4 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.